Company Poltreg S.A.

Equities

PTG

PLPLTRG00038

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Quarterly revenue - Rate of surprise

Sector Other Biotechnology & Medical Research

Market Closed - Warsaw S.E. Other stock markets 11:55:46 2024-07-16 am EDT			5-day change	1st Jan Change
49.1 ^PLN	-4.84%		-2.19%	-1.41%

Jun. 24	PolTREG?s Type-1 Diabetes Treg Cell Therapy PTG-007 Demonstrates Long-Term Safety and Efficacy for Up to 12 Years	CI
May. 23	Poltreg S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Poltreg SA is a Poland-based company engaged primarily in biotechnology and medical research. The Company conducts research in the field of autoimmunological diseases. The Company works on a method of healing, that uses t-regulated cells (TREGs). The Firm possesses its own, patented technology to obtain T-regulated lymphocytes, that are used in the therapy. The Company works on therapy for diseases such as type one diabetes, type two diabetes, and multiple sclerosis. In its research, the Company cooperates with multiple specialists from various fields of science. The Company is developing its own research center, which is intended as a basic location for conducting future research activities.

Number of employees: 26

PLN in Million	2022	Weight	2023	Weight	Delta
T-regulated Lymphocyte 100.0 %	1	100.0 %	1	100.0 %	+40.04%

PLN in Million	2022	Weight	2023	Weight	Delta
Poland 100.0 %	1	100.0 %	1	100.0 %	+40.04%

Managers	Title	Age	Since
Piotr Trzonkowski CEO	Chief Executive Officer	-	14-12-31
Paulina Kocenko-Merks DFI	Director of Finance/CFO	-	23-02-28
Marta Druch CTO	Chief Tech/Sci/R&D Officer	-	-
Kamilla Agnieszka Bok COO	Chief Operating Officer	-	18-06-30
Mariusz Jablonski PRN	Corporate Officer/Principal	-	19-12-08

Members of the board	Title	Age	Since
Oktawian Zbigniew Jaworek BRD	Director/Board Member	48	21-05-20
Artur Janusz Osuchowski BRD	Director/Board Member	49	21-07-14
Marcin Jerzy Mierzwiñski CHM	Chairman	-	21-05-23
Wojciech Golak BRD	Director/Board Member	41	-
Jacek Gdanski BRD	Director/Board Member	-	21-07-14

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	4,663,448	3,015,848 ( 64.67 %)	0	64.67 %

Name	Equities	%	Valuation
Paan Capital Sp zoo Spk 21.31 %	993,602	21.31 %	12 M zł
IPOPEMA TFI SA (Venture Capital) 19.83 %	924,789	19.83 %	12 M zł
Allianz Polska PTE SA 7.583 %	353,629	7.583 %	4 M zł
Trzonkowska Marek 5.243 %	244,499	5.243 %	3 M zł
Piotr Trzonkowski 5.243 %	244,499	5.243 %	3 M zł
Allianz Polska TFI SA 4.006 %	186,800	4.006 %	2 M zł
Malgorzata Mysliwiec 3.538 %	165,000	3.538 %	2 M zł
Artur Janusz Osuchowski 0.2680 %	12,500	0.2680 %	155 471 zł
Aviva Investors Poland Towarzystwo Funduszy Inwestycyjnych SA 0.000000 %	0	0.000000 %	- zł

PolTREG SA

ul. Botaniczna 20

80-298, Gdansk

+48 512 53 24 01

http://www.poltreg.com

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

51.6 PLN

Average target price

68.2 PLN

Spread / Average Target

+32.17%

Consensus

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
POLTREG S.A.	-1.61%	61.76M
MODERNA, INC.	+22.15%	46.56B
LONZA GROUP AG	+45.04%	41.67B
IQVIA HOLDINGS INC.	-2.37%	41.16B
ALNYLAM PHARMACEUTICALS, INC.	+33.84%	32.4B
CELLTRION, INC.	-6.35%	28.1B
ICON PUBLIC LIMITED COMPANY	+20.42%	28.18B
UNITED THERAPEUTICS CORPORATION	+48.83%	14.52B
MEDPACE HOLDINGS, INC.	+45.00%	13.74B
BIO-TECHNE CORPORATION	+0.06%	12.17B

Other Biotechnology & Medical Research